<DOC>
	<DOCNO>NCT00001929</DOCNO>
	<brief_summary>Patients Parkinson 's disease miss chemical neurotransmitter dopamine . This occur result destructive change area brain responsible make dopamine , basal ganglion . Patients disease experience , rigid muscle , stoop posture , shuffling-type walk ( gait ) . In study researcher plan evaluate effectiveness drug eliprodil treatment Parkinson 's Disease . Eliprodil work block special receptor ( NMDA ) associate symptom Parkinson 's Disease .</brief_summary>
	<brief_title>Treatment Parkinson 's Disease With Eliprodil</brief_title>
	<detailed_description>The objective study evaluate acute effect NR2B subtype-selective NMDA antagonist eliprodil levodopa-associated motor response complication patient advance Parkinson 's Disease ( PD ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Eliprodil</mesh_term>
	<criteria>All patient carry diagnosis idiopathic Parkinson 's Disease base presence characteristic clinical history neurologic finding . Most relatively advanced disease associate motor response complication . Males female age 1875 . No presence history medical condition reasonably expect subject patient unwarranted risk . No patient baseline QTc prolongation ( great 440 msec ) . No pregnant woman practice effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>Dyskinesias</keyword>
	<keyword>Glutamate Antagonist</keyword>
	<keyword>Levodopa</keyword>
</DOC>